Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
IRLAB Therapeutics AB Class A ( ($SE:IRLAB.A) ) has shared an update.
IRLAB Therapeutics AB has announced positive results from the second part of its Phase I study for IRL757, a drug candidate aimed at treating apathy in neurodegenerative diseases. The study, funded by The Michael J. Fox Foundation, showed that IRL757 is well absorbed and tolerated, supporting further clinical development. The company has initiated a Phase Ib study in collaboration with The McQuade Center for Strategic Research and Development, with plans to enroll the first patients in late 2025. This development positions IRLAB as a potential leader in addressing apathy, a significant unmet medical need in Parkinson’s and Alzheimer’s diseases.
More about IRLAB Therapeutics AB Class A
IRLAB Therapeutics AB is a Swedish company focused on discovering and developing transformative treatments for Parkinson’s disease and other neurodegenerative disorders. Originating from Nobel Laureate Prof Arvid Carlsson’s research group, the company is known for its innovative approach using a proprietary systems biology-based research platform. IRLAB’s pipeline includes several drug candidates, such as Mesdopetam and Pirepemat, targeting various stages and symptoms of Parkinson’s disease.
Average Trading Volume: 85,618
Current Market Cap: SEK371.4M
For detailed information about IRLAB.A stock, go to TipRanks’ Stock Analysis page.